These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20051446)

  • 1. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease.
    Marwick JA; Chung KF; Adcock IM
    Ther Adv Respir Dis; 2010 Feb; 4(1):19-34. PubMed ID: 20051446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease.
    Ito K; Caramori G; Adcock IM
    J Pharmacol Exp Ther; 2007 Apr; 321(1):1-8. PubMed ID: 17021257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?
    Thomas M; Owen C
    Curr Opin Pharmacol; 2008 Jun; 8(3):267-74. PubMed ID: 18394961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting phosphoinositide 3-kinase gamma to fight inflammation and more.
    Barberis L; Hirsch E
    Thromb Haemost; 2008 Feb; 99(2):279-85. PubMed ID: 18278175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies.
    Harris SJ; Foster JG; Ward SG
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1151-62. PubMed ID: 19876783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphoinositide 3-kinase delta inhibitor as a novel therapeutic agent in asthma.
    Park SJ; Min KH; Lee YC
    Respirology; 2008 Nov; 13(6):764-71. PubMed ID: 18811876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukocyte navigation mechanisms as targets in airway diseases.
    Medina-Tato DA; Watson ML; Ward SG
    Drug Discov Today; 2006 Oct; 11(19-20):866-79. PubMed ID: 16997136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?
    Rommel C; Camps M; Ji H
    Nat Rev Immunol; 2007 Mar; 7(3):191-201. PubMed ID: 17290298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function.
    Fung-Leung WP
    Cell Signal; 2011 Apr; 23(4):603-8. PubMed ID: 20940048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel signal transduction modulators for the treatment of airway diseases.
    Barnes PJ
    Pharmacol Ther; 2006 Jan; 109(1-2):238-45. PubMed ID: 16171872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.
    Doukas J; Eide L; Stebbins K; Racanelli-Layton A; Dellamary L; Martin M; Dneprovskaia E; Noronha G; Soll R; Wrasidlo W; Acevedo LM; Cheresh DA
    J Pharmacol Exp Ther; 2009 Mar; 328(3):758-65. PubMed ID: 19056934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future therapies for airway mucus hypersecretion.
    Barnes PJ
    Novartis Found Symp; 2002; 248():237-49; discussion 249-53, 277-82. PubMed ID: 12568498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biological effects of isoform-specific PI3-kinase inhibition.
    Ihle NT; Powis G
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):41-9. PubMed ID: 20047145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule inhibitors of cell signaling: novel future therapeutics for asthma and chronic obstructive pulmonary diseases.
    Blease K; Raymon HK
    Curr Opin Investig Drugs; 2003 May; 4(5):544-51. PubMed ID: 12833647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond.
    Medina-Tato DA; Ward SG; Watson ML
    Immunology; 2007 Aug; 121(4):448-61. PubMed ID: 17614878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis?
    Fougerat A; Gayral S; Malet N; Briand-Mesange F; Breton-Douillon M; Laffargue M
    Clin Sci (Lond); 2009 May; 116(11):791-804. PubMed ID: 19397491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elucidating the role of protein kinase C in chronic lymphocytic leukaemia.
    Michie AM; Nakagawa R
    Hematol Oncol; 2006 Sep; 24(3):134-8. PubMed ID: 16841369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signaling through PI3Kgamma: a common platform for leukocyte, platelet and cardiovascular stress sensing.
    Hirsch E; Lembo G; Montrucchio G; Rommel C; Costa C; Barberis L
    Thromb Haemost; 2006 Jan; 95(1):29-35. PubMed ID: 16543958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications.
    Weichhart T; Säemann MD
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii70-4. PubMed ID: 19022819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of class II phosphoinositide 3-kinase in cell signalling.
    Falasca M; Maffucci T
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):211-4. PubMed ID: 17371240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.